Elderly
Conditions
Interventions
Placebo food not containing curcumin
Highly absorbable curcumin: curcu-rouge
Sponsors
National Hospital Organization Kyoto Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Main Inclusion Criteria Elderly persons (aged 60 years or older, regardless of sex) will be recruited through posters or websites, and persons from the general population who have freely given consent in writing will be enrolled as subjects of the study. In addition, if a person who is taking an oral medication due to a lifestyle-related disease applies, enrollment will be possible after confirmation that s/he is active and stable. Definition of activity: ECOG performance status (PS): 0 or 1 Definition of stable state: (i) There is no change in the content and amount of oral medication within the 6-month period before the consent date (ii) No history of hospitalization within the 1-year period before the consent date
Exclusion criteria
Exclusion criteria: Persons who fall under any of the following criteria will be excluded from the study. 1) Persons who regularly consume health foods containing curcumin 2) Persons who have a history of allergy to curcumin 3) Persons who are pregnant or breastfeeding 4) Persons who undergoing treatment for malignant tumor 5) Persons who regularly take an antibiotic or steroid 6) Persons who are taking two or more antiplatelet agents or a single antiplatelet agent with another antithrombotic agent (e.g., anticoagulant, EPA agent, prostacyclin agent) 7) Persons who have a history of cerebral hemorrhage and are taking a single antiplatelet agent 8) Persons undergoing home oxygen therapy 9) Persons undergoing dialysis due to renal failure 10) Persons with severe liver dysfunction/cirrhosis 11) Persons with severe cardiac dysfunction (left ventricular ejection fraction less than 20%) 12) In addition, persons for whom the research director or co-researcherinvestigators determine to be inappropriate for participation in this research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymphocyte type and count (T cell count, CD4T cell count and CD8T cell cunt ratio, regulatory T cell count, naive T cell count and memory T cell count ratio, total CD28T cell count among CD8T cells, B cell count, NK cell count, and T cell proliferation coefficient) | — |
Secondary
| Measure | Time frame |
|---|---|
| LOX-index | — |
Countries
Japan
Contacts
Public ContactKoji Hasegawa
National Hospital Organization Kyoto Medical Center Division of Translational Research
Outcome results
None listed